Published in Neurology on April 11, 2006
Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun (2009) 2.37
Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology (2011) 1.23
Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcare. Mult Scler Int (2010) 1.20
Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J Neurol (2007) 1.01
A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis. PLoS One (2010) 1.00
Genetic contribution to multiple sclerosis risk among Ashkenazi Jews. BMC Med Genet (2015) 0.77
Impact of Medicare Part D on Racial and Ethnic Minorities. Divers Equal Health Care (2016) 0.75
Frequent misdiagnosis of adult polyglucosan body disease. J Neurol (2015) 0.75
Sociocultural and Demographic Risk Factors for the Development of Multiple Sclerosis in Kuwait: A Case - Control Study. PLoS One (2015) 0.75
Multiple sclerosis frequency in Israel's diverse populations. Neurology (2007) 0.75
Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet (2012) 2.98
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Testing the 8-syndrome structure of the child behavior checklist in 30 societies. J Clin Child Adolesc Psychol (2007) 1.94
Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev (2009) 1.93
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol (2006) 1.61
Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neurol (2008) 1.49
Telemedicine for multiple sclerosis patients: assessment using Health Value Compass. Mult Scler (2011) 1.45
The generalizability of the Youth Self-Report syndrome structure in 23 societies. J Consult Clin Psychol (2007) 1.45
Epidemiological comparisons of problems and positive qualities reported by adolescents in 24 countries. J Consult Clin Psychol (2007) 1.32
Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcare. Mult Scler Int (2010) 1.20
Comparisons of problems reported by youths from seven countries. Am J Psychiatry (2003) 1.18
Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res (2002) 1.15
Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev (2011) 1.13
Virtual reality cues for improvement of gait in patients with multiple sclerosis. Neurology (2006) 1.11
The imaging appearance of Creutzfeldt-Jakob disease caused by the E200K mutation. Magn Reson Imaging (2006) 1.07
Adapting the SRQ for Ethiopian populations: a culturally-sensitive psychiatric screening instrument. Transcult Psychiatry (2008) 1.05
Trends in the use of rehabilitation services in the community by people with mental disabilities in Israel; the factors involved. Isr J Health Policy Res (2012) 1.04
Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol (2012) 1.04
Home-based personalized cognitive training in MS patients: a study of adherence and cognitive performance. NeuroRehabilitation (2010) 1.02
Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-β and role played in cell migration. J Neuroimmunol (2010) 1.02
The ubiquitin-proteasome pathway regulates claudin 5 degradation. J Cell Biochem (2012) 0.99
Prevalence and risk factors of threshold and sub-threshold psychiatric disorders in primary care. Soc Psychiatry Psychiatr Epidemiol (2007) 0.99
Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol (2010) 0.96
Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci (2006) 0.96
Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. Mult Scler (2007) 0.95
Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. Am J Physiol Cell Physiol (2005) 0.95
New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci (2008) 0.93
Twelve-month service utilization rates for mental health reasons: data from the Israel National Health Survey. Isr J Psychiatry Relat Sci (2007) 0.93
Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain (2009) 0.93
Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry (2006) 0.92
Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci (2011) 0.92
The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol (2002) 0.91
Tight junction proteins expression and modulation in immune cells and multiple sclerosis. J Cell Mol Med (2012) 0.91
Auditory feedback control for improvement of gait in patients with Multiple Sclerosis. J Neurol Sci (2007) 0.89
Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubes. ACS Chem Neurosci (2011) 0.89
Predictors of cumulative length of psychiatric inpatient stay over one year: a national case register study. Isr J Psychiatry Relat Sci (2010) 0.88
Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol (2005) 0.87
Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis. J Neuroimmunol (2002) 0.86
Re-hospitalization of first-in-life admitted schizophrenic patients before and after rehabilitation legislation: a comparison of two national cohorts. Soc Psychiatry Psychiatr Epidemiol (2007) 0.85
Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. Expert Rev Neurother (2012) 0.84
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics (2007) 0.84
Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. J Cell Mol Med (2011) 0.84
In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun (2008) 0.84
Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. J Neurol Sci (2008) 0.84
Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells. PLoS One (2013) 0.84
Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse. Mult Scler (2010) 0.84
Emotional responses of children and adolescents to parents with multiple sclerosis. Mult Scler (2005) 0.83
Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol (2006) 0.83
Goal disengagement and goal re-engagement among multiple sclerosis patients: relationship to well-being and illness representation. Psychol Health (2009) 0.83
Prevalence of mood and anxiety disorders in the community: results from the Israel National Health Survey. Isr J Psychiatry Relat Sci (2007) 0.83
Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cells. J Neuroimmunol (2006) 0.82
The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta. J Neuroimmunol (2003) 0.82
Prevalence of myotonic dystrophy in Israeli Jewish communities: inter-community variation and founder premutations. Am J Med Genet A (2003) 0.82
Epidemiology of dementia in Ashkelon: the influence of education. J Neurol (2003) 0.82
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. J Neurol Sci (2003) 0.82
Post-discharge contact with mental health clinics and psychiatric readmission: a 6-month follow-up study. Isr J Psychiatry Relat Sci (2011) 0.82
Mediterranean weather conditions and exacerbations of multiple sclerosis. Neuroepidemiology (2010) 0.81
Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin (2007) 0.81
Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a Model. Drug News Perspect (2002) 0.81
Snord 3A: a molecular marker and modulator of prion disease progression. PLoS One (2013) 0.81
T cells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: role of IL-2. Autoimmun Rev (2013) 0.81
Dimethyl sulfoxide delays PrP sc accumulation and disease symptoms in prion-infected hamsters. Brain Res (2003) 0.80
Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. Int Immunol (2006) 0.80
Involvement of phosphodiesterases in autoimmune diseases. J Neuroimmunol (2010) 0.80
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA J (2010) 0.79
Patterns of psychiatric hospitalization among ethiopian and former soviet union immigrants and persons born in Israel. Psychiatr Serv (2009) 0.79
A polymorphism in the complement component C1r is not associated with sporadic Alzheimer's disease. Neurosci Lett (2003) 0.79
Regional effects on the mental health of immigrant children: results from the New Canadian Children and Youth Study (NCCYS). Health Place (2011) 0.79
Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol (2013) 0.78
The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun (2013) 0.78
Juvenile multiple sclerosis similar to type I diabetes mellitus has a seasonality of month of birth which differs from that in the general population. J Pediatr Endocrinol Metab (2008) 0.78
[Development of a culturally sensitive psychiatric screening instrument for detecting emotional problems among Ethiopian immigrants in Israel]. Harefuah (2002) 0.78
An association study of the codon 72 polymorphism in the pro-apoptotic gene p53 and Alzheimer's disease. Neurosci Lett (2003) 0.78
The frequency of multiple sclerosis in jewish and arab populations in greater jerusalem. Neuroepidemiology (2003) 0.78
The Fas promoter polymorphism at position -670 is not associated with late-onset sporadic Alzheimer's disease. Dement Geriatr Cogn Disord (2004) 0.78
Glide-symmetric locomotion reinforcement in patients with multiple sclerosis by visual feedback. Disabil Rehabil Assist Technol (2010) 0.78
Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's disease. Eur Neurol (2004) 0.78
Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cells. J Neuroimmunol (2002) 0.78
Mental disorders in primary care in Israel: prevalence and risk factors. Soc Psychiatry Psychiatr Epidemiol (2013) 0.77
Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. J Neuroimmunol (2009) 0.77
Immunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol (2002) 0.77
Estimating the changes in demand for public mental health services following changes in eligibility: analysis of national survey data. J Ment Health Policy Econ (2009) 0.77
Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis. J Neuroimmunol (2012) 0.76
Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect. J Clin Psychopharmacol (2009) 0.76
Physicians' influence on primary care patients' reluctance to use mental health treatment. Psychiatr Serv (2014) 0.76
An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2004) 0.75
Lack of association of interleukin-1beta polymorphism with Alzheimer's disease in the Jewish population. Neurosci Lett (2004) 0.75
Cognitive strategies application of multiple sclerosis patients. Mult Scler (2004) 0.75
Impact of a rehabilitation legislation on the survival in the community of long-term patients discharged from psychiatric hospitals in Israel. Soc Psychiatry Psychiatr Epidemiol (2006) 0.75
Utilization patterns of ambulatory psychiatric services by Ethiopian immigrants in Israel. Isr J Psychiatry Relat Sci (2012) 0.75
Neuroimmunology in Israel--2002: proceedings of the 2nd annual meeting of the Israel society of neuroimmunology. J Neuroimmunol (2002) 0.75
Characterization of sleep disorders in patients with E200K familial Creutzfeldt-Jakob disease. J Neurol (2014) 0.75
Shifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specific. Curr Opin Neurol (2016) 0.75
[Human transmissible spongiform encephalopathies]. Harefuah (2003) 0.75
Cognitive Function of Patients with Crohn's Disease is Associated with Intestinal Disease Activity. Inflamm Bowel Dis (2016) 0.75
Use of unconventional therapies by primary care patients--religious resources vs. complementary or alternative medicine services. Complement Ther Med (2013) 0.75
Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. J Neurol (2014) 0.75